SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

Published:2014-02 Issue:2 Volume:2 Page:125-132
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Inagaki Nobuya,Onouchi Hitoshi,Sano Hiroki,Funao Nobuo,Kuroda Shingo,Kaku Kohei

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference18 articles.

1. Treatment adherence in chronic disease;Dunbar-Jacob;J Clin Epidemiol,2001

2. Interventions for enhancing medication adherence;Haynes;Cochrane Database Syst Rev,2008

3. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes;Pladevall;Diabetes Care,2004

4. A systematic review of adherence with medications for diabetes;Cramer;Diabetes Care,2004

5. Variations in patients'adherence to medical recommendations: a quantitative review of 50 years of research;DiMatteo;Med Care,2004

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Structure-property Relationships of Clinically Approved Protease Inhibitors;Current Medicinal Chemistry;2024-04

2. A model‐informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor;Diabetes, Obesity and Metabolism;2023-11-12

3. Gender representation in drug development studies for diabetes mellitus. A systematic review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-08

4. Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents;Molecules;2022-09-15

5. Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling;Biomedicine & Pharmacotherapy;2022-09